Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma

Abstract. In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous therapies received Bendamustine (90 mg/m2, day 1 ...

Full description

Bibliographic Details
Main Authors: Georg Hess, Karola Wagner, Ulrich Keller, Paul La Rosee, Johannes Atta, Kai Hübel, Christian Lerchenmueller, Daniel Schoendube, Mathias Witzens-Harig, Christian Ruckes, Christoph Medler, Christina van Oordt, Wolfram Klapper, Matthias Theobald, Martin Dreyling
Format: Article
Language:English
Published: Wolters Kluwer 2020-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000398

Similar Items

Similar Items